Background/Aims A large percentage of patients undergoing esophagogastroduodenoscopy (EGD) screening do not have esophageal varices (EV) or have only small EV. We evaluated a large, international, multicenter cohort to develop a novel score, termed FIB-4plus, by combining the fibrosis-4 (FIB-4) score, liver stiffness measurement (LSM), and spleen stiffness measurement (SSM) to identify high-risk EV (HRV) in compensated cirrhosis.
Methods This international cohort study involved patients with compensated cirrhosis from 17 Chinese hospitals and one Croatian institution (NCT04546360). Two-dimensional shear wave elastography-derived LSM and SSM values, and components of the FIB-4 score (i.e., age, aspartate aminotransferase, alanine aminotransferase, and platelet count [PLT]) were combined using machine learning algorithms (logistic regression [LR] and extreme gradient boosting [XGBoost]) to develop the LR-FIB-4plus and XGBoost-FIB-4plus models, respectively. Shapley Additive exPlanations method was used to interpret the model predictions.
Results We analyzed data from 502 patients with compensated cirrhosis who underwent EGD screening. The XGBoost-FIB-4plus score demonstrated superior predictive performance for HRV, with an area under the receiver operating characteristic curve (AUROC) of 0.927 (95% confidence interval [CI] 0.897–0.957) in the training cohort (n=268), and 0.919 (95% CI 0.843–0.995) and 0.902 (95% CI 0.820–0.984) in the first (n=118) and second (n=82) external validation cohorts, respectively. Additionally, the XGBoost-FIB-4plus score exhibited high AUROC values for predicting EV across all cohorts. The FIB-4plus score outperformed the individual parameters (LSM, SSM, PLT, and FIB-4).
Conclusions The FIB-4plus score effectively predicted EV and HRV in patients with compensated cirrhosis, providing clinicians with a valuable tool for optimizing patient management and outcomes.
Citations
Citations to this article as recorded by
The evolution of non-invasive strategies in cirrhosis management—from screening to precision monitoring: Editorial on “Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an inter Haiyu Wang, Jinjun Chen Clinical and Molecular Hepatology.2026; 32(1): 403. CrossRef
Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Artificial Intelligence Applications in the Diagnosis and Management of Cirrhosis and Portal Hypertension: A Narrative Review Amrit Khooblall, Satish E. Viswanath, Layth Khawaja, Sameer Gadani Techniques in Vascular and Interventional Radiology.2025; 28(4): 101078. CrossRef
Liver stiffness measurement-based risk score for predicting liver decompensation risk: a single-center retrospective Chinese study Yanqiu Li, Zihang Qiao, Jinze Li, Yongqi Li, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Metabolomics and metabolites in cancer diagnosis and treatment Minyi Cai, Haiyan Liu, Chen Shao, Tingting Li, Jun Jin, Yahui Liang, Jinhu Wang, Ji Cao, Bo Yang, Qiaojun He, Xuejing Shao, Meidan Ying Molecular Biomedicine.2025;[Epub] CrossRef
Backgrounds/Aims Non-invasive models stratifying clinically significant portal hypertension (CSPH) are limited. Herein, we developed a new non-invasive model for predicting CSPH in patients with compensated cirrhosis and investigated whether carvedilol can prevent hepatic decompensation in patients with high-risk CSPH stratified using the new model.
Methods Non-invasive risk factors of CSPH were identified via systematic review and meta-analysis of studies involving patients with hepatic venous pressure gradient (HVPG). A new non-invasive model was validated for various performance aspects in three cohorts, i.e., a multicenter HVPG cohort, a follow-up cohort, and a carvediloltreating cohort.
Results In the meta-analysis with six studies (n=819), liver stiffness measurement and platelet count were identified as independent risk factors for CSPH and were used to develop the new “CSPH risk” model. In the HVPG cohort (n=151), the new model accurately predicted CSPH with cutoff values of 0 and –0.68 for ruling in and out CSPH, respectively. In the follow-up cohort (n=1,102), the cumulative incidences of decompensation events significantly differed using the cutoff values of <–0.68 (low-risk), –0.68 to 0 (medium-risk), and >0 (high-risk). In the carvediloltreated cohort, patients with high-risk CSPH treated with carvedilol (n=81) had lower rates of decompensation events than non-selective beta-blockers untreated patients with high-risk CSPH (n=613 before propensity score matching [PSM], n=162 after PSM).
Conclusions Treatment with carvedilol significantly reduces the risk of hepatic decompensation in patients with high-risk CSPH stratified by the new model.
Citations
Citations to this article as recorded by
Endoscopic variceal ligation combined with carvedilol versus endoscopic variceal ligation combined with propranolol for the treatment of oesophageal variceal bleeding in cirrhosis: study protocol for a multicentre, randomised controlled trial Yiling Li, Li Du, Shuairan Zhang, Chuan Liu, Chao Ma, Xiaochao Liu, Huanhai Xu, Zhixu Fan, Shengjuan Hu, Jing Wang, Lichun Shao, Lijun Peng, Huiling Xiang, Xuan Liang, Wenhui Zhang, Hongyun Zhao, Pengyuan He, Jingyi Xu, Qianlong Li, Ling Yang, Yunhai Wu, BMJ Open.2025; 15(4): e093866. CrossRef
Relative change rate of liver stiffness measurements predicts the risk of liver decompensation in compensated advanced chronic liver disease Yanqiu Li, Zihang Qiao, Jinze Li, Bingbing Zhu, Yu Lu, Ying Feng, Xianbo Wang Clinical and Experimental Medicine.2025;[Epub] CrossRef
Revolutionising portal hypertension diagnosis: the rise of non-invasive techniques in liver cirrhosis Bocheng Gao, Yumeng Lin, Huimin Zhang, Yulin Li, Shuhua Gou, Peiling Ma, Xueni Zhao, Yue Zhou, Qian Chen, Lan Yuan, Zhongyu Han, Chang Yu Frontiers in Medicine.2025;[Epub] CrossRef
Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis? Ling Yang, Chuan Liu, Jimmy Che‐To Lai, Xiaolong Qi Alimentary Pharmacology & Therapeutics.2024; 60(7): 965. CrossRef
Long non-coding RNAs (lncRNAs), a class of transcribed RNA molecules with the lengths exceeding 200 nucleotides, are not translated into protein. They can modulate protein-coding genes by controlling transcriptional and posttranscriptional processes. The dysregulation of lncRNAs has been related to various pathological disorders. In this review, we summarized the current knowledge of lncRNAs and their implications in the pathogenesis of three common liver diseases: nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease. Future studies to further define the role of lncRNAs and their mechanisms in various types of liver diseases should be explored. An improved understanding from these studies will provide us a useful perspective leading to mechanism-based intervention by targeting specific lncRNAs for the treatment of liver diseases.
Citations
Citations to this article as recorded by
LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism Zhihong Yang, Yanchao Jiang, Jing Ma, Li Wang, Sen Han, Nazmul Huda, Praveen Kusumanchi, Hui Gao, Themis Thoudam, Zhaoli Sun, Suthat Liangpunsakul Hepatology.2025; 81(5): 1485. CrossRef
Molecular mechanisms of lncRNA NEAT1 in the pathogenesis of liver-related diseases, with special focus on therapeutic approaches Yahui Wang, Gaurav Sanghvi, Suhas Ballal, RSK Sharma, Piyus Kumar Pathak, Aman Shankhyan, Jiaxuan Sun, Qingmin Chen, Yu Ma, Lei Huang, Yahui Liu Pathology - Research and Practice.2025; 269: 155867. CrossRef
Dynamic role of long noncoding RNA in liver diseases: pathogenesis and diagnostic aspects Ningning Chen, Yunxia Li, Xiaoying Li Clinical and Experimental Medicine.2025;[Epub] CrossRef
Physiological Mechanisms Vulnerable to Alcohol‐Induced Alterations: Role in Chronic Comorbidities Liz Simon, Kaitlin E. Couvillion, Meagan E. Donovan, Eden M. Gallegos, Flavia M. Souza‐Smith, Patricia E. Molina Comprehensive Physiology.2025;[Epub] CrossRef
The Role of miRNA and Long Noncoding RNA in Cholestatic Liver Diseases Yudian Zhang, Ying Liu, Wen Huo, Longfei He, Bowen Li, Hui Wang, Fanyin Meng, Chenggang Duan, Bingru Zhou, Jinbo Wu, Rong Chen, Juan Xing, Ying Wan The American Journal of Pathology.2024; 194(6): 879. CrossRef
LncRNA taurine upregulated gene 1 in liver disease Zihao Fan, Hao Pan, Na Qu, Xin Wang, Lianrui Cao, Lijiang Chen, Mingxia Liu Clinica Chimica Acta.2024; 560: 119752. CrossRef
Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes? Sina Kalantari Soltanieh, Sahar Khastar, Irwanjot Kaur, Abhishek Kumar, Jaya Bansal, Ata Fateh, Deepak Nathiya, Beneen Husseen, Mansour Rajabivahid, Mahmoud Dehghani-Ghorbi, Reza Akhavan-Sigari Cell Biochemistry and Biophysics.2024; 83(1): 279. CrossRef
LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation Lu Liu, Sen Sun, Xiaohua Li Clinics and Research in Hepatology and Gastroenterology.2023; 47(1): 102067. CrossRef
The function of long non-coding RNA in non-alcoholic fatty liver disease Lianrui Cao, Na Qu, Xin Wang, Lijiang Chen, Mingxia Liu Clinics and Research in Hepatology and Gastroenterology.2023; 47(3): 102095. CrossRef
LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review Qingmin Zeng, Chang-Hai Liu, Dongbo Wu, Wei Jiang, Nannan Zhang, Hong Tang Biomolecules.2023; 13(3): 560. CrossRef
Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities Wiramon Rungratanawanich, Jacob W. Ballway, Xin Wang, Kyoung-Jae Won, James P. Hardwick, Byoung-Joon Song Pharmacology & Therapeutics.2023; 251: 108547. CrossRef
Elucidating the Influence of MPT-driven necrosis-linked LncRNAs on immunotherapy outcomes, sensitivity to chemotherapy, and mechanisms of cell death in clear cell renal carcinoma Jinbang Huang, Mengtao Liu, Haiqing Chen, Jinhao Zhang, Xixi Xie, Lai Jiang, Shengke Zhang, Chenglu Jiang, Jieying Zhang, Qinhong Zhang, Guanhu Yang, Hao Chi, Gang Tian Frontiers in Oncology.2023;[Epub] CrossRef
Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis Zhihong Yang, Sen Han, Ting Zhang, Praveen Kusumanchi, Nazmul Huda, Kelsey Tyler, Kristina Chandler, Nicholas J. Skill, Wanzhu Tu, Mu Shan, Yanchao Jiang, Jessica L. Maiers, Kristina Perez, Jing Ma, Suthat Liangpunsakul Hepatology Communications.2022; 6(6): 1361. CrossRef
Management of liver diseases: Current perspectives Gautam Ray World Journal of Gastroenterology.2022; 28(40): 5818. CrossRef
Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium Zhu Xue, Juanli Li, Jiaxing Feng, Han Han, Jing Zhao, Jiao Zhang, Yanhua Han, Xiaoke Wu, Yuehui Zhang Frontiers in Physiology.2021;[Epub] CrossRef
First
Prev
